Biogen is discontinuing its Alzheimer’s drug Aduhelm, which was approved in 2021 but became snarled in efficacy concerns and payers’ refusals to cover the medication.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
Biogen abandons controversial Alzheimer's drug Aduhelm
